Infantile neuronal ceroid lipofuscinosis

Jan 29, 2020

REGENXBIO Announces Presentations at the 16th Annual WORLDSymposium(TM) 2020

Jan 20, 2020

Polaryx Therapeutics Receives IND Approval for PLX-200 From the FDA for the Treatment of Late Infantile Neuronal Ceroid Lipofuscinosis

Dec 23, 2019

Polaryx Therapeutics Submits Investigational New Drug Application to the U.S. FDA for the Treatment of Late Infantile Neuronal Ceroid Lipofuscinosis With PLX-200

Dec 07, 2019

Mallinckrodt Presents Data on a Novel Predictive Model to Identify Infants at Risk for Infantile Spasms (IS) at the 2019 Annual Meeting of the American Epilepsy Society (AES)

Jun 09, 2018

Global Batten Community Unites To Launch Inaugural International Batten Disease (NCL) Awareness Day

Feb 26, 2018

Polaryx Therapeutics Received Orphan Drug Designation From the European Medicines Agency (EMA) for the Treatment of Neuronal Ceroid Lipofuscinosis With PLX-200

Dec 11, 2017

Polaryx Therapeutics Receives Orphan Drug Designation From the US FDA for the Treatment of Neuronal Ceroid Lipofuscinoses With PLX-100